Federated Hermes Inc. Makes New $53.09 Million Investment in Atyr PHARMA INC (NASDAQ:ATYR)

Federated Hermes Inc. purchased a new position in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 14,666,600 shares of the company's stock, valued at approximately $53,093,000. Federated Hermes Inc. owned about 17.47% of Atyr PHARMA as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. lifted its position in Atyr PHARMA by 52.0% during the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company's stock worth $55,000 after buying an additional 10,754 shares during the period. Kingswood Wealth Advisors LLC purchased a new stake in shares of Atyr PHARMA during the 4th quarter valued at about $170,000. Alterna Wealth Management Inc. acquired a new position in shares of Atyr PHARMA during the fourth quarter worth $36,000. D.A. Davidson & CO. acquired a new position in Atyr PHARMA in the 4th quarter worth $141,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Atyr PHARMA during the 4th quarter valued at approximately $144,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Atyr PHARMA Stock Performance

Shares of ATYR traded up $0.23 during mid-day trading on Friday, reaching $2.97. 2,188,219 shares of the company's stock traded hands, compared to its average volume of 895,516. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The business's 50-day moving average price is $3.46 and its 200-day moving average price is $3.27. The stock has a market capitalization of $263.91 million, a P/E ratio of -3.16 and a beta of 0.95. Atyr PHARMA INC has a 12 month low of $1.42 and a 12 month high of $4.66.

Remove Ads

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. Equities analysts predict that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Analysts Set New Price Targets

ATYR has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $35.00 target price on shares of Atyr PHARMA in a report on Friday, March 14th. Cantor Fitzgerald assumed coverage on Atyr PHARMA in a research note on Monday, January 6th. They issued an "overweight" rating for the company. Leerink Partners began coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price target on the stock. Finally, Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $18.60.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.